Production of no-carrier added 67Cu

A two-stage method is described for the purification of Cu radionuclides from up to 5 g of nat Zn and other radionuclides. After proton bombardment, co-produced 66,67 Ga is removed by passing the dissolved zinc in 7 M HCl through a 2.5 ml column of AmberChrom CG-71, a methacrylate-based polymeric resin. This first column eluate, which contains 65 Zn, 64,67 Cu, and 56,57,58 Co, is taken to incipient dryness and reconstituted in 300 ml 0.05 M HCl. This solution is then pumped through a novel 10 ml column of dithizone impregnated AmberChrom CG-71, where Cu radionuclides are efficiently retained with no breakthrough. Zinc and Co radionuclides elute smoothly during washing with no tailing. More than 97 % Cu is eluted by washing with 40 ml 5 M HNO 3 warmed to 50 ºC. No dithizone is detected in this eluate.

show abstract

“…5,6,7], and electrolysis [8,9]. Schwarzbach et al [10] performed a comparison of these methods, indicating anion exchange as the most effective.…”

Section: Introductionmentioning

confidence: 99%

The production and isolation of Cu-64 and Cu-67 from zinc target material and other radionuclides

et al. 2006

View full text Add to dashboard Cite

show abstract

“…These methods provide sufficient quantities of 67 Cu with high specific activity and adequate radioactive purity. The production yield of 67 Cu at 200 MeV proton energy is 4.2 mCi mA À1 h À1 [48]. In a 3-d irradiation with 200 MeV protons, 100 mCi can be produced from a 4-g zinc target.…”

Section: Radionuclide Production From Cyclotronsmentioning

confidence: 99%

Radionuclides, 2. Radioactive Elements and Artificial Radionuclides

Keller¹,

Wolf

Shani

2011

Ullmann's Encyclopedia of Industrial Chemistry

View full text Add to dashboard Cite

“…However, as mentioned earlier in this article, the use of Cu-67 has been inhibited by a lack of regular availability of sufficient quantities at a cost that researchers can typically afford, as well as the low specific activity issue. 7,21 In the past several decades, the most typical source in the United States has been the high energy proton irradiation of natural Zn targets, 21 primarily irradiated at either the BLIP (Brookhaven Linac Isotope Producer) at BNL or at the Isotope Production Facility (IPF) at LANL (Los Alamos National Laboratory). These are both large accelerators operated and funded for physics research only part of each year.…”

Section: Copper-67mentioning

confidence: 99%

“…21 It provides medium energy emission of 0.6 MeV max (average, 141 keV), photon emissions (184 keV, 48.7%; 93 keV, 16%; 91 keV, 7%), and facile labeling chemistry. It is a very attractive theragnostic radionuclide.…”

Section: Copper-67mentioning

confidence: 99%

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Srivastava¹

2013

Journal of Postgraduate Medicine, Education and Research

View full text Add to dashboard Cite

This article deals primarily with the selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and evaluated, and those that warrant future investigations. Various scientific and practical issues related to the production and availability of these radionuclides is briefly addressed. At brookhaven national laboratory (BNL), we have developed a paradigm that involves specific individual 'dual-purpose' radionuclides or radionuclide pairs with emissions suitable for both imaging and therapy, and which when molecularly (selectively) targeted using appropriate carriers, would allow pre-therapy low-dose imaging plus higher-dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may thus potentially bring us closer to the age-long dream of personalized medicine for performing tailored low-dose molecular imaging (SPECT/CT or PET/CT) to provide the necessary pretherapy information on biodistribution, dosimetry, the limiting or critical organ or tissue, and the maximum tolerated dose (MTD), etc., followed by performing higher-dose targeted molecular therapy in the same patient with the same radiopharmaceutical. As an example, our preclinical and clinical studies with the theragnostic radionuclide Sn-117m are covered in somewhat greater detail.A troublesome problem that remains yet to be fully resolved is the lack of availability, in sufficient quantities and at reasonable cost, of a majority of the best candidate theragnostic radionuclides in a no-carrier-added (NCA) form. In this regard, a summary description of recently developed new or modified methods at BNL for the production of five theragnostic radionuclide/radionuclide pair items, whose nuclear, physical, and chemical characteristics seem to show promise for therapeutic oncology and for treating other disorders that respond to radionuclide therapy, is provided.

show abstract

Production of no-carrier added 67Cu

Cited by 90 publications

References 27 publications

The production and isolation of Cu-64 and Cu-67 from zinc target material and other radionuclides

The production and isolation of Cu-64 and Cu-67 from zinc target material and other radionuclides

Radionuclides, 2. Radioactive Elements and Artificial Radionuclides

A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals

Contact Info

Product

Resources

About